Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06307652 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
A Phase 3 study of Heart Failure and Impaired Kidney Function, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,800
- Enrollment target
- 20
- Study locations
NCT06307652 is a Phase 3 study of Heart Failure and Impaired Kidney Function that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,800 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06307652, a Phase 3 study of Heart Failure and Impaired Kidney Function, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Conditions Studied
Interventions
- DRUG balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- DRUG balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- DRUG dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Study Locations (20)
California
- Research Site - Beverly Hills
- Research Site - Covina
- Research Site - Encinitas
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Orange
- Research Site - Redding
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - San Francisco
- Research Site - Santa Ana
- Research Site - Thousand Oaks
Alabama
- Research Site - Alexander City
- Research Site - Birmingham
- Research Site - Fairhope
- Research Site - Huntsville
Arizona
- Research Site - Phoenix
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,800 participants |
| Start Date | 2024-04-12 |
| Est. Completion | 2027-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06307652
The ClinicalTrials.gov registry entry for NCT06307652 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure and Impaired Kidney Function appearing as the primary indexed condition, and to 3 interventions - of which balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg is the first listed.
NCT06307652 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06307652 about?
NCT06307652 is a clinical study titled "Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function". This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapag...
What is the current status of trial NCT06307652?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,800 participants. The study started on 2024-04-12. Estimated completion is 2027-06-11.
What conditions does trial NCT06307652 study?
This clinical trial studies the following conditions: Heart Failure and Impaired Kidney Function.
What interventions are being tested in trial NCT06307652?
The interventions under investigation include: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG), balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (DRUG), dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06307652?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06307652 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.